Cadila Healthcare Ltd share analysis 2017

CADILAHC stock short term technical analysis

CADILAHC stock today closed at 352 with almost 7% drop. Technically stock today given broke down below major support of 365 rupee. Below it now short term trend will be down. On downside 321 and 285 are major support zones as well as target zone for current downtrend. Future traders below 365 can keep sell on rise view and expect targets of 321 to 285 in February series. Daily closing above 365 will be trend reversal signal for targets 400 and 444. Daily chart indicators and oscillators also suggesting less downside and more upside for stock in short terms. Cadila Healthcare Ltd share analysis 2017

CADILAHC stock long term technical analysis

CADILAHC share for 2017, above 359 will remain buy and accumulate for technical targets of 426 and 497. But now trading below 359 and if gives 1-2 weekly closing below 359 means downtrend for stock in 2017 with bearish targets of 289 and then 221. But current weekly chart indicators and price pattern suggest stock will have limited downside from long term view and will show 426 to 497 till end of 2017. cadila healthcare ltd logo

Cadila Healthcare Ltd company description

Cadila Healthcare Limited is an India-based pharmaceutical company. The Company’s subsidiaries include Zydus Wellness Limited, Liva Pharmaceuticals Limited, Biochem Pharmaceutical Industries Limited, Zydus Technologies Limited, German Remedies Limited, Dialforhealth India Limited, Dialforhealth Unity Limited and Dialforhealth Greencross Limited, among others.

The Author

Pramod Baviskar

Professional Market Trader And Owner Of Dalal Street Winners Advisory And Coaching Services. Working Since 2007 And Online Presence Since 2010. We Provide Highly Accurate And Professional 1 Entry And 1 Exit Future, Option, Commodity, Currency And Intraday Stock Tips On Whatsapp With Live Support And Follow Up.
COPYRIGHT © 2017. Pramod Baviskar. Dalal street winners advisory and coaching services. FAQ | Disclaimer | Privacy Policy

This website is best viewed using Microsoft Internet Explorer 9 or higher, and/or latest version of Google Chrome and Mozila Firefox browsers.